Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

IntroductionIn 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapril...

Full description

Bibliographic Details
Main Authors:	Pei Yang, Xiaokang Li, Lijin Wang, Xinlei Wu, Chiyao Wang, Tian Li, Haiyan Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	sacubitril valsartan acute myocardial infarction coronary intervention retrospective study
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.1059420/full

Similar Items

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
by: Pema Raj, et al.
Published: (2021-08-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction
by: Fan H, et al.
Published: (2023-02-01)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
by: Pei Yang, et al.
Published: (2022-08-01)

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats
by: Mohd Imran, et al.
Published: (2019-01-01)

A clinical randomized trial: Effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in acute myocardial infarction patients
by: Zhengfeng Liu, et al.
Published: (2024-12-01)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
by: Hsin‐Ti Huang, et al.
Published: (2022-12-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies
by: Hisham A. Badreldin, et al.
Published: (2022-02-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
by: Marina Nikolic, et al.
Published: (2022-11-01)

Sacubitril/Valsartan Alleviates Cardiac Remodeling and Dysfunction in L-NAME-Induced Hypertension and Hypertensive Heart Disease
by: Peter Stanko, et al.
Published: (2024-03-01)

Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial Infarction
by: Zhao L, et al.
Published: (2024-12-01)

Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF
by: Henan Liu, et al.
Published: (2024-04-01)

Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR‐181a in a Rodent Chronic Myocardial Infarction Model
by: Evgeniya Vaskova, et al.
Published: (2020-07-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
by: Liu Yang, et al.
Published: (2022-08-01)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
by: Sara Monosilio, et al.
Published: (2022-05-01)

Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure
by: Maura Brioschi, et al.
Published: (2023-03-01)

Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
by: Wenqi Tao, et al.
Published: (2023-06-01)

Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization
by: Krisztina Mária Szabó, et al.
Published: (2024-01-01)

Cardiopulmonary exercise test-based assessment of the effects of sacubitril/valsartan on the blood pressure response to exercise in patients with acute myocardial infarction during hospitalization
by: Chun-Mei Zeng, et al.
Published: (2022-07-01)

A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction
by: Xiaomin Zhou, et al.
Published: (2022-10-01)

Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024
by: Diana Carina Iovanovici, et al.
Published: (2024-06-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
by: Shuangcui Wang, et al.
Published: (2023-05-01)

Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients
by: Bin Wang, et al.
Published: (2022-03-01)

Changes in urinary output due to concomitant administration of sacubitril/valsartan and atrial natriuretic peptide in patients with heart failure: a multicenter retrospective cohort study
by: Tatsuki Yanagawa, et al.
Published: (2024-09-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
by: Iacopo Fabiani, et al.
Published: (2023-10-01)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
by: Magnus O. Wijkman, et al.
Published: (2022-06-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Frecuencia y distribución geográfica del uso de sacubitril/valsartán en Colombia entre los años 2019 y 2020
by: Nancy Herrera-Leaño, et al.
Published: (2024-01-01)

Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure
by: Marina V. Vitsenya, et al.
Published: (2023-09-01)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
by: Amr Abdin, et al.
Published: (2022-12-01)

Effects and clinical outcomes of early initiation of sacubitril/valsartan in patients with chronic heart failure with a low ejection fraction
by: Z. D. Kobalava, et al.
Published: (2020-12-01)

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia
by: Alshammari A, et al.
Published: (2024-01-01)

Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out‐of‐Pocket Costs
by: Birju R. Rao, et al.
Published: (2023-04-01)

First signs of reverse cardiac remodeling following one-month, low dose add-on sacubitril-valsartan therapy in patients with advanced systolic heart failure
by: Wioletta Sacharczuk, et al.
Published: (2022-03-01)